2022 was a rough year for the stock market. Nearly all sectors were dragged down amid economic uncertainty, fueled by rising interest rates. Nonetheless, companies with solid fundamentals can weather any storm over the long run. Diversifying one’s portfolio with stocks from various industries that offer promising long-term growth is a smart way to make money through stock investing.
The healthcare sector is usually resilient in times of macroeconomic uncertainties mainly because healthcare isn’t something consumers can postpone indefinitely. So diversifying one’s investments across various industries in this sector is a prudent way to increase one’s wealth. Vertex Pharmaceuticals (VRTX 1.37%), Intuitive Surgical (ISRG -1.16%), and cannabis company Green Thumb Industries (GTBIF 0.12%) are three stocks that offer potential long-term rewards. Let’s see why.
Vertex Pharmaceuticals has a robust upcoming pipeline
Boston-based Vertex Pharmaceuticals is a biotechnology company whose cystic fibrosis (CF) drugs have proven to be a huge success. These drugs should continue to drive the company’s long-term success. Trikafta is currently Vertex’s best-selling CF treatment. That drug alone generated $5.6 billion in revenue in the nine months ending 2022, out of a total of $6.6 billion in product revenue.
For the same period, the company’s bottom line jumped 61% year over year to $9.68 per share.
At the end of the third quarter of 2022, Vertex had a robust cash balance of $9.8 billion, which could continue fueling development in new drugs.
Currently, Vertex generates 100% of its revenue from CF drugs. However, management has been working toward potentially diversifying its revenue sources. The company’s research and development pipeline of drugs includes drug trials for sickle cell disease and beta thalassemia, developed in collaboration with CRISPR Therapeutics . In short, Vertex’s strong drug pipeline could propel it to a larger and more diverse business in the next…
Read complete post here: